Cell Expansion Market Health Improvement Aspects, Expert Reviews, Research 2018 to 2026

Cell expansion is the large scale artificial production of daughter cells from a single cell, to support medical research. Rising preference for regenerative medicines offering faster results, and emergence of cell-based therapies with high patient compatibility are expected to fuel the cell expansion market during the forecast period (2017–2025). Regenerative medicine helps the body to form new functional tissue to replace defective or lost ones providing treatment for conditions with inadequate therapies. According to the U.S. Department of Health and Services, in 2016, NIH invested around US$ 1.5 billion in stem cell research projects. Increasing government and private sector expenditure on cell-based research therapies is expected to boost growth of the market for cell expansion in the near future. The number of FDA approvals for clinical trials of stem cell-based treatments is rapidly increasing. According to a report published by Pharmaceutical Research and Manufacturers of America, in 2013, around 69 cell therapies with clinical trials were under review with the FDA.

Get A Sample Copy Of This Research Report: www.coherentmarketinsights.com/insight/request-sample/1293

Key players operating in the cell expansion market include Becton, Dickinson and Company, Beckman Coulter, Inc., Corning, Inc., GE Healthcare, Lonza, Merck KGaA (Sigma-Aldrich Co. LLC), Miltenyi Biotec, Thermo Fisher Scientific, Inc., Terumo BCT, Inc., and Stemcell Technologies, Inc. In July 2016, GE Healthcare acquired Biosafe SA, a Swiss company that manufactures instruments that recover stem cells and help in various other cell processing procedures related to personalized medicine. This acquisition will help GE Healthcare to grow the cells in the sample for appropriate dose sizes.

Increasing incidence of chronic medical conditions is expected to boost growth of the cell expansion market over the forecast period

The increasing cases of chronic and rare medical conditions around the world is another key factor driving demand for cell expansion. For instance, according to World Health Organization (WHO), around 15 million people are projected to suffer from cancer by 2020. The rising prevalence of cancer, is in turn, expected to boost growth of the cell expansion market. Cell-based therapy is also a promising approach for treating chronic kidney disease and is presently the focus of preclinical studies. Recent advancements in regenerative medicine and tissue engineering have created cell-based approaches for the treatment of renal failure. Such treatments include biotechnological approach using implantation of bioengineered kidney constructs, transplanting cells, and bio-artificial renal systems.

The number of FDA approvals for clinical trials of stem cell-based treatments is rapidly increasing. According to a report published by Pharmaceutical Research and Manufacturers of America, in 2013, around 69 cell therapies with clinical trials were under review with the FDA. The therapeutic classes represented in these trials include skin diseases, cardiovascular diseases, transplantations, eye conditions, cancer and associated conditions, musculoskeletal disorders, genetic disorders, and digestive disorders.

According to the U.S. Department of Health and Services, in 2016, NIH invested around US$ 1.5 billion in stem cell research projects. Increasing government and private sector expenditure on cell-based research therapies is expected to boost growth of the market for cell expansion in the near future. The number of FDA approvals for clinical trials of stem cell-based treatments is rapidly increasing. According to a report published by Pharmaceutical Research and Manufacturers of America, in 2013, around 69 cell therapies with clinical trials were under review with the FDA.

Click To Read More On Cell Expansion Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.